 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LISINOPRIL increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Lisinopril"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LISINOPRIL: indications_and_usage: INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood [0m
[31mpressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a[0m
[31mwide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as [0m
[31mappropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure [0m
[31mgoals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâ€™s Joint National Committee on Prevention, Detection, [0m
[31mEvaluation, and Treatment of High Blood Pressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. LISINOPRIL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of [0m
[31maction, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic [0m
[31mproperty of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in [0m
[31mmyocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg [0m
[31mis greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. LISINOPRIL: indications_and_usage: Relative risk reduction from blood [0m
[31mpressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, [0m
[31mpatients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood [0m
[31mpressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients, and many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. [0m
[31mThese considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. LISINOPRIL: indications_and_usage: In using [0m
[31mlisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients [0m
[31mwith renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In considering use of lisinopril and[0m
[31mhydrochlorothiazide tablets, it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-Black. [0m[1;31m([0m[31mSee WARNINGS, Head and [0m
[31mNeck Angioedema .         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: adverse_reactions: Discontinuation of therapy due to adverse effects was required in [0m[1;31m4.4[0m[31m% of patients principally because of dizziness, cough, fatigue and muscle cramps. Adverse [0m
[31mexperiences occurring in greater than one percent of patients treated with lisinopril plus hydrochlorothiazide in controlled clinical trials are shown below. Percent of Patients in Controlled Studies [0m
[31mClinical adverse experiences occurring in [0m[1;31m0.3[0m[31m% to [0m[1;31m1.0[0m[31m% of patients in controlled trials included: Lisinopril-Hydrochlorothiazide [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m930[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m207[0m[1;31m)[0m[31m Incidence Dizziness[0m
[1;31m7.5[0m[31m [0m[1;31m([0m[1;31m0.8[0m[1;31m)[0m[31m [0m[1;31m1.9[0m[31m Headache [0m[1;31m5.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m1.9[0m[31m Cough [0m[1;31m3.9[0m[31m [0m[1;31m([0m[1;31m0.6[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Fatigue [0m[1;31m3.7[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Orthostatic Effects [0m[1;31m3.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m. LISINOPRIL: adverse_reactions: [0m[1;31m0[0m[31m Diarrhea [0m[1;31m2.5[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Upper [0m
[31mRespiratory Infection [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.0[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Muscle Cramps [0m[1;31m2.0[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Asthenia [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m1.0[0m[31m Paresthesia [0m[1;31m1.5[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Hypotension [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Vomiting [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.5[0m[31m Dyspepsia [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.0[0m[1;31m)[0m[31m [0m[1;31m0.0[0m[31m Rash [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m
[1;31m0.5[0m[31m Impotence [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. LISINOPRIL: adverse_reactions: [0m[1;31m0[0m[31m Body as a Whole: Chest pain, abdominal pain, syncope, chest discomfort, fever, trauma, virus infection. Cardiovascular: Palpitation, [0m
[31morthostatic hypotension. Digestive: Gastrointestinal cramps, dry mouth, constipation, heartburn. Musculoskeletal: Back pain, shoulder pain, knee pain, back strain, myalgia, foot pain. [0m
[31mNervous/Psychiatric: Decreased libido, vertigo, depression, somnolence. Respiratory: Common cold, nasal congestion, influenza, bronchitis, pharyngeal pain, dyspnea, pulmonary congestion, chronic [0m
[31msinusitis, allergic rhinitis, pharyngeal discomfort. Skin: Flushing, pruritus, skin inflammation, diaphoresis. Special Senses: Blurred vision, tinnitus, otalgia. Urogenital: Urinary tract infection. [0m
[31mLISINOPRIL: adverse_reactions: Angioedema: Angioedema has been reported in patients receiving PRINZIDE, with an incidence higher in Black than in non-Black patients. Angioedema associated with [0m
[31mlaryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with PRINZIDE should be discontinued and appropriate therapy instituted [0m
[31mimmediately. In rare cases, intestinal angioedema has been reported with angiotensin converting enzyme inhibitors including lisinopril. [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. Hypotension: In clinical trials, adverse [0m
[31meffects relating to hypotension occurred as follows: hypotension [0m[1;31m([0m[1;31m1.4[0m[31m percent[0m[1;31m)[0m[31m, orthostatic hypotension [0m[1;31m([0m[1;31m0.5[0m[31m percent[0m[1;31m)[0m[31m, other orthostatic effects [0m[1;31m([0m[1;31m3.2[0m[31m percent[0m[1;31m)[0m[31m. In addition syncope occurred in [0m[1;31m0.8[0m[31m [0m
[31mpercent of patients [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. LISINOPRIL: adverse_reactions: Cough: See PRECAUTIONS - Cough . Clinical Laboratory Test Findings Serum Electrolytes: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Creatinine, Blood Urea [0m
[31mNitrogen: Minor reversible increases in blood urea nitrogen and serum creatinine were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide tablets. More [0m
[31mmarked increases have also been reported and were more likely to occur in patients with renal artery stenosis [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and [0m
[31mCalcium: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.5[0m[31m g% and [0m[1;31m1.5[0m[31m vol%, respectively[0m[1;31m)[0m[31m occurred frequently in [0m
[31mhypertensive patients treated with lisinopril and hydrochlorothiazide tablets but were rarely of clinical importance unless another cause of anemia coexisted. LISINOPRIL: adverse_reactions: In [0m
[31mclinical trials, [0m[1;31m0.4[0m[31m% of patients discontinued therapy due to anemia. Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. [0m[1;31m([0m[31mSee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. [0m
[31mOther adverse reactions that have been reported with the individual components are listed below: Lisinopril - In clinical trials adverse reactions which occurred with lisinopril were also seen with [0m
[31mlisinopril and hydrochlorothiazide tablets. LISINOPRIL: adverse_reactions: In addition, and since lisinopril has been marketed, the following adverse reactions have been reported with lisinopril and [0m
[31mshould be considered potential adverse reactions for lisinopril and hydrochlorothiazide tablets: Body as a Whole: Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid and Possibly Related Reactions [0m[1;31m)[0m[31m,[0m
[31mmalaise, edema, facial edema, pain, pelvic pain, flank pain, chills; Cardiovascular: Cardiac arrest, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in [0m
[31mhigh risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m, pulmonary embolism and infarction, worsening of heart failure, arrhythmias [0m[1;31m([0m[31mincluding tachycardia, ventricular tachycardia, atrial tachycardia, atrial [0m
[31mfibrillation, bradycardia, and premature ventricular contractions[0m[1;31m)[0m[31m, angina pectoris, transient ischemic attacks LISINOPRIL: adverse_reactions: , paroxysmal nocturnal dyspnea, decreased blood pressure,[0m
[31mperipheral edema, vasculitis; Digestive: Pancreatitis, hepatitis [0m[1;31m([0m[31mhepatocellular or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, gastritis, anorexia, flatulence, increased salivation; [0m
[31mEndocrine: Diabetes mellitus, syndrome of inappropriate antidiuretic hormone secretion [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m; Hematologic: Rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported.[0m
[31mLISINOPRIL: adverse_reactions: Hemolytic anemia has been reported; a causal relationship to lisinopril cannot be excluded; Metabolic: Gout, weight loss, dehydration, fluid overload, weight gain; [0m
[31mMusculoskeletal: Arthritis, arthralgia, neck pain, hip pain, joint pain, leg pain, arm pain, lumbago; Nervous System/Psychiatric: Ataxia, memory impairment, tremor, insomnia, stroke, nervousness, [0m
[31mconfusion, peripheral neuropathy [0m[1;31m([0m[31me.g. LISINOPRIL: adverse_reactions: paresthesia, dysesthesia[0m[1;31m)[0m[31m, spasm, hypersomnia, irritability, mood alterations [0m[1;31m([0m[31mincluding depressive symptoms[0m[1;31m)[0m[31m; hallucinations ; [0m
[31mRespiratory: Malignant lung neoplasms, hemoptysis, pulmonary edema, pulmonary infiltrates, eosinophilic pneumonitis, bronchospasm, asthma, pleural effusion, pneumonia, wheezing, orthopnea, painful [0m
[31mrespiration, epistaxis, laryngitis, sinusitis, pharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; Skin: Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin infections, [0m
[31mpemphigus, erythema, psoriasis.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: spl_id         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: mechanism_of_action: Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme [0m[1;31m([0m[31mACE[0m[1;31m)[0m[31m in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the [0m
[31mconversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma [0m
[31mangiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Removal of angiotensin II [0m
[31mnegative feedback on renin secretion leads to increased plasma renin activity. In hypertensive patients with normal renal function treated with lisinopril alone for up to [0m[1;31m24[0m[31m weeks, the mean increase [0m
[31min serum potassium was less than [0m[1;31m0.1[0m[31m mEq/L; however, approximately [0m[1;31m15[0m[31m percent of patients had increases greater than [0m[1;31m0[0m[31m. LISINOPRIL: mechanism_of_action: [0m[1;31m5[0m[31m mEq/L and approximately six percent had a [0m
[31mdecrease greater than [0m[1;31m0.5[0m[31m mEq/L. In the same study, patients treated with lisinopril plus a thiazide diuretic showed essentially no change in serum potassium. [0m[1;31m([0m[31mSee PRECAUTIONS .[0m[1;31m)[0m[31m ACE is identical to [0m
[31mkininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated. [0m
[31mWhile the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients [0m
[31mwith low-renin hypertension. LISINOPRIL: mechanism_of_action: Although lisinopril was antihypertensive in all races studied, Black hypertensive patients [0m[1;31m([0m[31musually a low-renin hypertensive population[0m[1;31m)[0m[31m [0m
[31mhad a smaller average response to lisinopril monotherapy than non-Black patients.         [0m
[31mSOURCE:LISINOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Lisinopril is indicated for the treatment of hypertension and lowering blood pressure, which in turn lowers the risk of fatal and non-fatal cardiovascular events, including myocardial [0m
[32minfarctions. Controlled trials of antihypertensive drugs, including lisinopril, have regularly shown reductions in myocardial infarction and cardiovascular mortality. Therefore, lisinopril is [0m
[32massociated with a decrease in the risk of myocardial infarction as part of its blood pressure-lowering effects.[0m

[32mSOURCE: LISINOPRIL label[0m
[32mEXTRACT_START_END: Lowering blood pressure lowers the risk [0m[32m...[0m[32m reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.[0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Lisinopril is indicated for the treatment of hypertension[0m
[34mand lowering blood pressure, which in turn lowers the risk of fatal and non-fatal cardiovascular events, including myocardial infarctions. Controlled trials of antihypertensive drugs, including [0m
[34mlisinopril, have regularly shown reductions in myocardial infarction and cardiovascular mortality. Therefore, lisinopril is associated with a decrease in the risk of myocardial infarction as part of [0m
[34mits blood pressure-lowering effects.[0m

[34mSOURCE: LISINOPRIL label[0m
[34mEXTRACT_START_END: Lowering blood pressure lowers the risk [0m[34m...[0m[34m reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.[0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LISINOPRIL increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that LISINOPRIL is indicated for the treatment of hypertension and that lowering blood pressure with LISINOPRIL lowers the risk of fatal and non-fatal cardiovascular [0m
[32mevents, including myocardial infarctions. Controlled trials have regularly shown reductions in myocardial infarction and cardiovascular mortality with antihypertensive drugs, including LISINOPRIL."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"LISINOPRIL is associated with a decrease in the risk of myocardial infarction as part of its blood pressure-lowering effects."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LISINOPRIL increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LISINOPRIL increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that LISINOPRIL is indicated for the treatment of hypertension and that lowering blood pressure with LISINOPRIL lowers the risk of fatal and non-fatal cardiovascular [0m
[34mevents, including myocardial infarctions. Controlled trials have regularly shown reductions in myocardial infarction and cardiovascular mortality with antihypertensive drugs, including LISINOPRIL."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"LISINOPRIL is associated with a decrease in the risk of myocardial infarction as part of its blood pressure-lowering effects."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LISINOPRIL increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LISINOPRIL increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that LISINOPRIL is indicated for the treatment of hypertension and that lowering blood pressure with LISINOPRIL lowers the risk of fatal and non-fatal cardiovascular events, [0m
[31mincluding myocardial infarctions. Controlled trials have regularly shown reductions in myocardial infarction and cardiovascular mortality with antihypertensive drugs, including LISINOPRIL.[0m
[31m        -----[0m
[31m        Final answer: LISINOPRIL is associated with a decrease in the risk of myocardial infarction as part of its blood pressure-lowering effects.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mLISINOPRIL is associated with a decrease in the risk of myocardial infarction as part of its blood pressure-lowering effects. Controlled trials of antihypertensive drugs, including lisinopril, have [0m
[32mregularly shown reductions in myocardial infarction and cardiovascular mortality.[0m
